Mario Occhipinti

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

Alessio Cortellini, Melissa Bersanelli, Sebastiano Buti et al. · Journal for ImmunoTherapy of Cancer · 2019 · 415 citations · Full text

Medicine, Immunology, Oncology +16

Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice

Alessio Cortellini, Marco Tucci, Vincenzo Adamo et al. · Journal for ImmunoTherapy of Cancer · 2020 · 264 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden

Daniele Marinelli, Marco Mazzotta, Stefano Scalera et al. · Annals of Oncology · 2020 · 223 citations · Full text

Medicine, Molecular Biology, Oncology +16

Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study

Alessandro Russo, Marco Russano, Tindara Franchina et al. · Advances in Therapy · 2020 · 168 citations

Medicine, Immunology, Oncology +17

Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index

Sebastiano Buti, Melissa Bersanelli, Fabiana Perrone et al. · European Journal of Cancer · 2020 · 117 citations

Life Sciences, Immunology, Oncology +17